Cardiotoxicity of Immune Checkpoint Inhibitors: An Updated Review

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Cardiotoxicity of Immune Checkpoint Inhibitors: An Updated Review Publisher Pubmed

Behravesh S¹ ; Shomali N² ; Danbaran GR¹ ; Aslani S³ ; Hemmatzadeh M² ; Hosseinzadeh R³ ; Gowharishabgah A⁴ ; Mohammadi H^{5, 6}

Source: Biotechnology and Applied Biochemistry Published:2022

Abstract

The immune checkpoint molecules are involved in the regulation of T cells in order to prevent them from attacking to sell tissues and play a role in the immune response homeostasis. Application of the immune checkpoint inhibitors (ICIs) has provided a promising therapeutic approach in pathologies where the immune system is suppressed. The extended utilization of ICIs in several cancers has caused immune-related side effects in the cardiovascular system like cardiomyopathy and myocarditis. Cardiac toxicity, one of the main side effects of the ICIs-based therapeutic approach, has less been concerned; however, during the last years, many cases of fatal heart failure and myocarditis have been reported in patients treated with ICIs. In this review article, we attempted to discuss the cardiac adverse effects of inhibiting different immune checkpoint molecules. © 2020 International Union of Biochemistry and Molecular Biology, Inc.

Related Docs

View other Related Docs

1. Immune Checkpoint Inhibitors and Cardiotoxicity: Possible Mechanisms, Manifestations, Diagnosis and Management, Expert Review of Anticancer Therapy (2021)

2. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)

3. Immune Checkpoint Inhibition for Pancreatic Cancer, Acta Medica Iranica (2023)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (11)

Ayat Ahmadi Saraeilani (1)

Other Related Docs

4. Immune Checkpoint Inhibition in Covid-19: Risks and Benefits, Expert Opinion on Biological Therapy (2021)

5. Interaction Between Cardiac Resynchronization Therapy and Cytokines in Heart Failure Patients, Cytokine (2024)

6. Current and Future Perspectives of Pd-1/Pdl-1 Blockade in Cancer Immunotherapy, Journal of Immunology Research (2021)

7. Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer: From Immunological Mechanisms to Clinical Evidence, International Immunopharmacology (2021)

8. Chemotherapy: A Double-Edged Sword in Cancer Treatment, Cancer Immunology# Immunotherapy (2022)

9. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)

10. The Molecular Landscape of T Cell Exhaustion in the Tumor Microenvironment and Reinvigoration Strategies, International Reviews of Immunology (2024)

11. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)

12. Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer, Immunotherapy (2021)

13. Evaluation of the Preventive Effects of Carvedilol on Trastuzumab-Induced Cardiotoxicity in Early-Stage and Locally Advanced Her2-Positive Breast Cancer Patients, International Journal of Hematology-Oncology and Stem Cell Research (2021)

14. Natural Killer Cells As Critical Modulators of Heart Disease: Exploring Pathophysiological Mechanisms and Therapeutic Perspectives, Iranian journal of allergy, asthma, and immunology (2025)

15. Anti-Ctla-4 Nanobody As a Promising Approach in Cancer Immunotherapy, Cell death & disease (2024)

16. Empagliflozin Treatment of Cardiotoxicity: A Comprehensive Review of Clinical, Immunobiological, Neuroimmune, and Therapeutic Implications, Biomedicine and Pharmacotherapy (2023)

17. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)

18. Tumor Immunology, Clinical Immunology (2022)

19. Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma, Expert Review of Anticancer Therapy (2021)

20. Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Breast Cancer: A Systematic Review and Meta-Analysis, International Immunopharmacology (2021)

Style	Citing Format
MLA	Behravesh S, et al.. "Cardiotoxicity of Immune Checkpoint Inhibitors: An Updated Review." Biotechnology and Applied Biochemistry, vol. 69, no. 1, 2022, pp. 61-69.
APA	Behravesh S, Shomali N, Danbaran GR, Aslani S, Hemmatzadeh M, Hosseinzadeh R, Gowharishabgah A, Mohammadi H (2022). Cardiotoxicity of Immune Checkpoint Inhibitors: An Updated Review. Biotechnology and Applied Biochemistry, 69(1), 61-69.
Chicago	Behravesh S, Shomali N, Danbaran GR, Aslani S, Hemmatzadeh M, Hosseinzadeh R, Gowharishabgah A, Mohammadi H. "Cardiotoxicity of Immune Checkpoint Inhibitors: An Updated Review." Biotechnology and Applied Biochemistry 69, no. 1 (2022): 61-69.
Harvard	Behravesh S et al. (2022) 'Cardiotoxicity of Immune Checkpoint Inhibitors: An Updated Review', Biotechnology and Applied Biochemistry, 69(1), pp. 61-69.
Vancouver	Behravesh S, Shomali N, Danbaran GR, Aslani S, Hemmatzadeh M, Hosseinzadeh R, et al.. Cardiotoxicity of Immune Checkpoint Inhibitors: An Updated Review. Biotechnology and Applied Biochemistry. 2022;69(1):61-69.
BibTex	@article{ author = {Behravesh S and Shomali N and Danbaran GR and Aslani S and Hemmatzadeh M and Hosseinzadeh R and Gowharishabgah A and Mohammadi H}, title = {Cardiotoxicity of Immune Checkpoint Inhibitors: An Updated Review}, journal = {Biotechnology and Applied Biochemistry}, volume = {69}, number = {1}, pages = {61-69}, year = {2022} }
RIS	TY - JOUR AU - Behravesh S AU - Shomali N AU - Danbaran GR AU - Aslani S AU - Hemmatzadeh M AU - Hosseinzadeh R AU - Gowharishabgah A AU - Mohammadi H TI - Cardiotoxicity of Immune Checkpoint Inhibitors: An Updated Review JO - Biotechnology and Applied Biochemistry VL - 69 IS - 1 SP - 61 EP - 69 PY - 2022 ER -

Science Communicator Platform

Authors

Abstract